TNM Staging System — The Standard for Cancer Staging

The TNM staging system was developed by the Union for International Cancer Control (UICC) and is maintained in collaboration with the American Joint Committee on Cancer (AJCC). It evaluates three essential anatomical components: 'T' represents the size and local invasiveness of the primary tumour; 'N' reflects whether the cancer has spread into regional lymph nodes and how many are affected; and 'M' indicates whether the disease has metastasised to distant organs or tissues.

Each letter is assigned a numerical score or suffix (such as T1 to T4, N0 to N3, and M0 or M1) based on radiological imaging, physical examinations, and histopathological analysis. Clinical staging (cTNM) is established before therapy commences, whereas pathological staging (pTNM) incorporates operative findings and microscopic evaluation of excised tissue, providing an authoritative baseline for multidisciplinary care teams.

Accurate TNM staging is fundamental to cancer management because it directly dictates treatment strategy. For example, early-stage disease may require local therapies like surgery or radiotherapy alone, whereas higher TNM categories often necessitate systemic chemotherapy, immunotherapy, or multi-modality approaches. Staging also provides reliable prognostic information, facilitates clinical trial enrolment, and ensures that clinicians across the globe communicate using clear, standardised terminology when discussing a patient's case.

TNM staging incorporates diagnostic imaging such as computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET) scans. Pathological staging requires biopsies, sentinel lymph node dissection, or surgical removal of the primary tumour. In modern revisions, anatomical TNM is frequently integrated with molecular biomarkers, including tumour grade, hormone receptor status, and genomic assays.

The TNM system is applied to the vast majority of solid malignancies, including lung, breast, colorectal, prostate, stomach, and melanoma cancers. It is not utilised for liquid tumours, such as acute or chronic leukaemias, because haematological cancers circulate widely through the bloodstream and bone marrow from onset and lack discrete primary tumours or regional nodal pathways that conform to the TNM model.

A lower TNM stage (e.g., T1 N0 M0) typically leads to curative-intent curative surgical resection or localised radiotherapy, occasionally followed by adjuvant therapy. Conversely, presence of nodal involvement (N1-N3) often introduces neoadjuvant or adjuvant systemic chemotherapy to reduce recurrence risks. Distant metastasis (M1) shifts treatment intent predominantly toward systemic disease control using targeted therapies, immunotherapy, or palliative interventions to prolong life and maintain quality of life.